Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)

Pulmonary Arterial Hypertension (PAH) is a chronic rare disease that can lead to serious cardiovascular problems and death. Additional treatments that increase effectiveness, that are safe and with a convenien...

Source: Orphanet Journal of Rare Diseases - December 10, 2018 Category: Internal Medicine Authors: Alberto Jim énez, Arantza Ais, Amélie Beaudet and Alicia Gil Tags: Research Source Type: research